Imperial Innovations Group Plc has appointed Peter Chambré and Linda Wilding as non-executive directors. Mr Chambré has held a number of senior executive and non-executive positions in the healthcare industry including as chief executive of Cambridge Antibody Technology Group Plc until its acquisition by AstraZeneca Plc in 2006. He currently chairs four companies in the healthcare sector including Cancer Research Technology.
Ms Wilding has worked in private equity and healthcare including as an executive at Mercury Asset Management. She is currently chair of the HG Capital Private Equity Valuation Committee and a non-executive director of UDG Healthcare Plc.
Imperial Innovations announced the appointments on 2 June 2014.
Copyright 2014 Evernow Publishing Ltd